search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Efficacy of addition of hrHPV testing by Hybrid Capture II to conventional cytological screening for cervical cancer: 5 years follow-up.


- candidate number5917
- NTR NumberNTR1850
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR10-jun-2009
- Secondary IDsTC 215  NTR
- Public TitleEfficacy of addition of hrHPV testing by Hybrid Capture II to conventional cytological screening for cervical cancer: 5 years follow-up.
- Scientific TitleEfficacy of addition of hrHPV testing by Hybrid Capture II to conventional cytological screening for cervical cancer: 5 years follow-up.
- ACRONYMVUSA-SCREEN
- hypothesisIn the original study (NTR215), we assessed the 3-year risk of CIN3+ in women stratified for hrHPV and cytology at baseline. In this study, we will assess the 5-year risks. Stratification at baseline is done on hrHPV, cytology, and hrHPV genotype. The results will be used to assess the optimal screening algorithm with hrHPV testing and to determine the length of the screening interval.
- Healt Condition(s) or Problem(s) studiedCervical intraepithelial neoplasia (CIN), Cervix cancer
- Inclusion criteria1. Women invited for the cervical cancer screening program (ages 30-60 years);
2. General practitioner affiliated with SALTRO laboratory.
- Exclusion criteria1. Not called for screening, i.e., ages under 30 years, or over 60 years;
2. Follow-up of previous non-normal cytology within the current screening round of the program, i.e., abnormal cytology or lesion ˇÝCIN3 less than 2 years before inclusion;
3. Current pregnancy;
4. Status after extirpation of the uterus or amputation of the portio.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingTriple
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-okt-2003
- planned closingdate1-dec-2010
- Target number of participants50000
- InterventionsIn the VUSA-SCREEN, women participating the regular cervical screening program were offered high-risk human papillomavirus (hrHPV) test, using the commercially available and FDA approved Hybrid Capture II test, in addition to cytology or cytology only. In order to improve detection of precursor lesions of cervical cancer, hrHPV is evaluated using a cohort study of women whose smears were consecutively screened at a single laboratory in The Netherlands. Within this cohort study, we nested an unblinded trial of women with mildly abnormal screening smears and repeat and referral recommendations were based on the presence or absence of high-risk human papillomavirus. Secondly, we nested a randomized trial of women with normal cytology whose hrHPV test results were triple blinded to participants, treating clinicians and study personnel, and advised all women with blinded test results to repeat cervical screening at earlier intervals than current screening guidelines in the Netherlands recommend in order to evaluate screening strategies for women with normal cytology and a positive hrHPV test.
- Primary outcomeThe primary outcome measure of VUSA-SCREEN is the occurrence of histologically confirmed cervical intra-epithelial neoplasia grade 3 (CIN3) lesions or (micro-) invasive carcinoma of the cervix found during the follow-up of currently diagnosed abnormalties, i.e., within 5 years. For women whose cytology results either regress to normal (in the unblinded trial of women with mild cytological abnormalities) or who clear an infection with hrHPV without cytological abnormalities (in the blinded trial of women with normal cytology diagnoses), we assume that no precursor lesions of cervical cancer are present. They will not be referred for colposcopically-directed biopsies and therefore will not have a histological endpoint. This policy complies with regular cervical screening in The Netherlands.
- Secondary outcomeAs a secondary outcome measure, histologically confirmed cervical intra-epithelial neoplasia grade 2 will also be investigated, since current guidelines recommend ablative treatment for these lesions as well.
Other secondary parameters obtained include progression and regression of cytology diagnoses, clearance and acquisition of hrHPV infections and the number of referrals for colposcopically-directed biopsies.
- TimepointsN/A
- Trial web siteN/A
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIESDrs. D.C. Rijkaart
- CONTACT for SCIENTIFIC QUERIESProf. C.J.L.M. Meijer
- Sponsor/Initiator SALTRO - Doctor Laboratory & Thrombosis Service
- Funding
(Source(s) of Monetary or Material Support)
SALTRO - Doctor Laboratory & Thrombosis Service
- PublicationsN/A
- Brief summaryCervical cancer almost exclusively develops in the presence of high-risk types of the human papillomavirus (hrHPV). A prolonged and persistent infection of the cervix with hrHPV is necessary for the development of premalignant (cervical intra-epithelial neoplasia, CIN) and finally malignant lesions. Prolonged presence of hrHPV types will lead to cytomorphological aberrations that can be detected in a cervical smear.
Research has shown that borderline and mild dyskaryotic (BMD) lesions tested positive for hrHPV significantly increase the risk for lesions ˇÝCIN3, and that progression to lesions ˇÝCIN3 will not occur in the absence of hrHPV. Secondly, women with normal smears (Pap 1) positive for hrHPV have a significantly increased risk for the development of lesions ˇÝCIN3. Thus, we will investigate the efficacy of additional testing for hrHPV in the cervical cancer screening program both for women with normal smears (Pap 1) and for women with BMD smears (Pap 2-3a1).
In this study, hrHPV testing will be performed by the Hybrid Capture II test (HCII). The HCII is a commercially available and FDA-approved test for hrHPV. This study has been designed as a population-based cohort study with a follow-up period of 5 years, in which 50,000 women invited for program-based screening in a geographically defined region in the Netherlands will participate. All participants will undergo at least the routine strategy for repeat smears and referrals as is the standard level of care in the program-based screening in the Netherlands. Most participants (> 80%) will not even undergo a different treatment, as they will be diagnosed Cervical cancer almost exclusively develops in the presence of high-risk types of the human papillomavirus (hrHPV). A prolonged and persistent infection of the cervix with hrHPV is necessary for the development of premalignant (cervical intra-epithelial neoplasia, CIN) and finally malignant lesions. Prolonged presence of hrHPV types will lead to cytomorphological aberrations that can be detected in a cervical smear. Research has shown that borderline and mild dyskaryotic (BMD) lesions tested positive for hrHPV significantly increase the risk for lesions ˇÝCIN3, and that progression to lesions ˇÝCIN3 will not occur in the absence of hrHPV. Secondly, women with normal smears (Pap 1) positive for hrHPV have a significantly increased risk for the development of lesions ˇÝCIN3. Thus, we will investigate the efficacy of additional testing for hrHPV in the cervical cancer screening program both for women with normal smears (Pap 1) and for women with BMD smears (Pap 2-3a1). In this study, hrHPV testing will be performed by the Hybrid Capture II test (HCII). The HCII is a commercially available and FDA-approved test for hrHPV. This study has been designed as a population-based cohort study with a follow-up period of 5 years, in which 50,000 women invited for program-based screening in a geographically defined region in the Netherlands will participate. All participants will undergo at least the routine strategy for repeat smears and referrals as is the standard level of care in the program-based screening in the Netherlands. Most participants (> 80%) will not even undergo a different treatment, as they will be diagnosed with hrHPV negative normal cytology (Pap 1). The extra care in this study will involve: 1. Women with hrHPV positive BMD (Pap 2-3a1) who will be referred to the gynaecologist for colposcopy immediately, as the presence of lesions ˇÝCIN3 will be expected solely in this group, and not in the group of women with hrHPV negative BMD;
2. All women with hrHPV positive normal cytology and 12.5% of the women with hrHPV negative cytology will undergo extra cytologic control to evaluate the role of hrHPV in the development of cytologic and histologic lesion. For these women, the hrHPV results will be blinded for the duration of the study.
In order to evaluate the hrHPV-based referral strategies with the regular repeat and referral recommendations, we compare the results of the study cohort with a cohort of women screened with conventional cytological testing only in the same period, region and study laboratory.

The research questions that will be answered in the study include the following:
1. Can women with BMD and a positive HCII hrHPV test be referred to the gynaecologist immediately, whereas women with a negative hrHPV test will be referred back to the regular screening program, without an increase in risk of missing lesions ˇÝCIN3?
2. Is the risk of lesions ˇÝCIN3 for women with hrHPV negative BMD not increased compared to women with normal cytology (Pap 1) and an unknown result of the HCII hrHPV test (i.e. women who are at present given an advice to repeat the smear after 5 years in the Netherlands)?
3. To what extent will lesions ˇÝCIN3 and/or cytologic progression to ˇÝ moderate dyskaryosis develop in women with HCII hrHPV positive normal cytology (Pap 1) compared to women diagnosed with HCII hrHPV negative normal cytology (Pap 1)?
4. Will the repeat and referral strategy based on classical cytology and HCII hrHPV testing not result in less women diagnosed with lesions ˇÝCIN3 for the women with BMD, than in a historical cohort of women diagnosed with BMD in the preceding year in the program-based cervical cancer screening?
5. Can the efficacy and cost effectiveness of the cervical screening programme be improved by increasing the screening interval for women with normal cytology and a negative hrHPV test?
6. What is the 5 years risk of ˇÝCIN3 lesions for women with normal cytology and a negative hrHPV test?
7. What is the 3 years risk of ˇÝCIN3 lesions for women with normal cytology and a negative hrHPV test at baseline and after 2 years?
8. What is the 5 years risk of ˇÝCIN3 lesions for women with normal cytology and a hrHPV positive test?
9. What are the HPV type specific 5 years risks of ˇÝCIN3 lesions?
10. What is the 5 years risk of ˇÝCIN3 lesions for baseline additionally tested molecular markers?
- Main changes (audit trail)
- RECORD10-jun-2009 - 30-sep-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl